Interaction between the skeletal and immune systems in cancer: Mechanisms and clinical implications

Cancer Immunology, Immunotherapy

Volumn 60, Issue 3, 2011, Pages 305-317

  Terpos, Evangelos ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anticancer; Bisphosphonates; Denosumab; Osteoimmunology; RANKL inhibition; Zoledronic acid

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CLODRONIC ACID; DENOSUMAB; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; IBANDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL ACTIVATION; CELL INTERACTION; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DRUG TARGETING; HEMATOPOIESIS; HUMAN; IMMUNOSTIMULATION; LUNG CANCER; MOLECULAR INTERACTION; MULTIPLE MYELOMA; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; BONE DISEASE; IMMUNOLOGY; IMMUNOPATHOLOGY; NEOPLASM; PATHOPHYSIOLOGY;

BONE DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 79953813491     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-0974-x     Document Type: Review

References (126)

1. Lorenzo J, Horowitz M, Choi Y (2008) Osteoimmunology: interactions of the bone and immune system. Endocr Rev 29:403-440 (Pubitemid 351831507)
2. Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292-304
3. Caetano-Lopes J, Canhao H, Fonseca JE (2009) Osteoimmunology - the hidden immune regulation of bone. Autoimmun Rev 8:250-255
4. Gohda J, Akiyama T, Koga T, Takayanagi H, Tanaka S, Inoue J (2005) RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J 24:790-799 (Pubitemid 40396108)
5. Kadono Y, Okada F, Perchonock C, Jang HD, Lee SY, Kim N, Choi Y (2005) Strength of TRAF6 signalling determines osteoclastogenesis. EMBO Rep 6:171-176 (Pubitemid 40309415)
6. Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J (2001) Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 20:1271-1280 (Pubitemid 32233967)
7. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T (2004) Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428:758-763 (Pubitemid 38508286)
8. Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R (2006) PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest 116:2869-2879 (Pubitemid 44684472)
9. Mocsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, Spusta SC, Majumdar S, Lanier LL, Lowell CA, Nakamura MC (2004) The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 101:6158-6163 (Pubitemid 38520544)
10. Ross FP, Teitelbaum SL (2005) alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev 208:88-105 (Pubitemid 41746387)
11. Sato K, Suematsu A, Nakashima T, Takemoto-Kimura S, Aoki K, Morishita Y, Asahara H, Ohya K, Yamaguchi A, Takai T, Kodama T, Chatila TA, Bito H, Takayanagi H (2006) Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med 12:1410-1416 (Pubitemid 44924500)
12. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319 (Pubitemid 27199902)
13. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137-142 (Pubitemid 27267548)
14. Wagner EF, Eferl R (2005) Fos/AP-1 proteins in bone and the immune system. Immunol Rev 208:126-140 (Pubitemid 41746389)
15. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y (1998) The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem 273:28355-28359 (Pubitemid 28496137)
16. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS 3rd, Frankel WN, Lee SY, Choi Y (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:25190-25194 (Pubitemid 27415705)
17. Gururajan P, Gurumurthy P, Nayar P, Babu S, Sarasabharati A, Victor D, Cherian KM (2009) Increased serum concentrations of soluble CD40 ligand as a prognostic marker in patients with acute coronary syndrome. Indian J Clin Biochem 24:229-233
18. Montecucco F, Steffens S, Mach F (2007) The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clin Dev Immunol 2007:75805
19. Chakraborty S, Cheek J, Sakthivel B, Aronow BJ, Yutzey KE (2008) Shared gene expression profiles in developing heart valves and osteoblast progenitor cells. Phys Genomics 35:75-85
20. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901 (Pubitemid 35460788)
21. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, Mak TW, Serfling E, Takayanagi H (2005) Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202:1261-1269 (Pubitemid 41586956)
22. Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP (2006) NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Gene 372:92-102
23. Kim Y, Sato K, Asagiri M, Morita I, Soma K, Takayanagi H (2005) Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J Biol Chem 280:32905-32913 (Pubitemid 41368340)
24. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, Hisatake K, Nogi Y (2004) Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 279:45969-45979 (Pubitemid 39491590)
25. Herman S, Kronke G, Schett G (2008) Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 14:245-253
26. Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS (2008) The cell biology of bone metabolism. J Clin Pathol 61:577-587 (Pubitemid 351678208)
27. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600-605
28. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T (2002) RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416:744-749 (Pubitemid 34429151)
29. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481-1488 (Pubitemid 32038586)
30. Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L (2004) RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 19:207-213 (Pubitemid 38116734)
31. Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F, Kim JH, Kobayashi T, Odgren PR, Nakano H, Yeh WC, Lee SK, Lorenzo JA, Choi Y (2005) Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 202:589-595 (Pubitemid 41248411)
32. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y (2006) Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 24:33-63
33. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673-2682 (Pubitemid 44833343)
34. David JP (2007) Osteoimmunology: a view from the bone. Adv Immunol 95:149-165
35. Askenasy N, Kaminitz A, Yarkoni S (2008) Mechanisms of T regulatory cell function. Autoimmun Rev 7:370-375
36. Kim YG, Lee CK, Nah SS, Mun SH, Yoo B, Moon HB (2007) Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells. Biochem Biophys Res Commun 357:1046-1052 (Pubitemid 46693677)
37. Kelchtermans H, Geboes L, Mitera T, Huskens D, Leclercq G, Matthys P (2009) Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis. Ann Rheum Dis 68:744-750
38. Biswas SK, Lewis CE (2010) NF-jB as a central regulator of macrophage function in tumors. J Leukoc Biol 88:877-884
39. Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE (2009) Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood 113:3139-3146
40. Pantel K, Alix-Panabieres C, Riethdorf S (2009) Cancer micrometastases. Nat Rev Clin Oncol 6:339-351
41. Raimondi C, Gradilone A, Gandini O, Petracca A, Nicolazzo C, Palazzo A, Naso G, Cortesi E, Gazzaniga P (2010) Circulating tumor cells in breast cancer: are currently available detection methods enough? (abstract 170PD). In: Presented at the 35th ESMO Congress, 8-12 Oct 2010, Milan, Italy
42. De Giorgi U, Mego M, Scarpi E, Handy BC, Jackson SA, Reuben J, Valero V, Hortobagyi GN, Ueno N, Cristofanilli M (2010) Relationship between lymphopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer (abstract 171PD). In: Presented at the 35th ESMO Congress, 8-12 Oct 2010, Milan, Italy
43. Sastre J, Maestro ML, Gomez MA, Rivera Herrero F, Valladares M, Massuti B, Gallen M, Benavides M, Diaz Rubio E, Aranda E (2010) Enumeration circulating tumor cells (CTCs) is a prognostic and predictive factor for progression-free survival (PFS) and overall survival (OS) in colon cancer patients receiving first-line chemotherapy plus bevacizumab. A TTD Spanish Group Cooperative Study (abstract 173PD). In: Presented at the 35th ESMO Congress, 8-12 Oct 2010, Milan, Italy
44. Seeliger H, Spatz H, Jauch KW (2003) Minimal residual disease in gastric cancer. Recent Results Cancer Res 162:79-87
45. Passlick B (2001) Micrometastases in non-small cell lung cancer (NSCLC). Lung Cancer 34(suppl 3):S25-S29
46. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, Vessella RL (2009) Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 15:677-683
47. Roodman GD, Dougall WC (2008) RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 34:92-101
48. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21-33
49. Hjorth-Hansen H, Seifert MF, Borset M, Aarset H, Ostlie A, Sundan A, Waage A (1999) Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 14:256-263
50. Orr W, Varani J, Gondex MK, Ward PA, Mundy GR (1979) Chemotactic responses of tumor cells to products of resorbing bone. Science 203:176-179
51. Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Redini F (2007) DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone 40:981-990
52. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692-696
53. Manishen WJ, Sivananthan K, Orr FW (1986) Resorbing bone stimulates tumor cell growth. A role for the host microenvironment in bone metastasis. Am J Pathol 123:39-45
54. Kostenuik PJ, Singh G, Suyama KL, Orr FW (1992) A quantitative model for spontaneous bone metastasis: evidence for a mitogenic effect of bone on Walker 256 cancer cells. Clin Exp Metastasis 10:403-410
55. Kostenuik PJ, Singh G, Suyama KL, Orr FW (1992) Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone. Clin Exp Metastasis 10:411-418
56. Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29:155-192
57. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL (2001) Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57:611-616
58. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, Findlay DM, Bardy P, Zannettino AC (2003) Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63:5438-5445
59. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC (2003) RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101:2094-2098
60. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140:4451-4458
61. Kitazawa S, Kitazawa R (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198:228-236
62. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E (2001) Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100:18-24
63. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM (2003) Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9:2587-2597
64. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001) Myeloma cells induce imbalance in the osteoprotegerin/ osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527-3533
65. Okada T, Akikusa S, Okuno H, Kodaka M (2003) Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. Clin Exp Metastasis 20:639-646
66. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S, Hojden M, Sammarelli G, Barille S, Bataille R, Rizzoli V (2002) Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100:4615-4621
67. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A (2002) Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100:3002-3007
68. Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D (2003) Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163:2021-2031
69. Schilbach K, Geiselhart A, Handgretinger R (2001) Induction of proliferation and augmented cytotoxicity of gammadelta T lymphocytes by bisphosphonate clodronate. Blood 97:2917-2918
70. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 340:1049-1052
71. Laakso M, Lahtinen R, Virkkunen P, Elomaa I (1994) Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Br J Haematol 87:725-729
72. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100:317-325
73. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT (2001) Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113:1035-1043
74. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65
75. Dearnaley DP, Mason MD, Parmar MKB, Sanders K, Sydes MR (2009) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10:872-876
76. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334:488-493
77. Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CR, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD (2002) Effects of long-term intravenous ibandronate therapy on skeletal- related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20:2353-2359
78. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377-387
79. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321
80. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613-2621
81. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882
82. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132-5139
83. Coxon FP, Thompson K, Rogers MJ (2006) Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6:307-312
84. Thompson K, Roelofs AJ, Jauhiainen M, Monkkonen H, Monkkonen J, Rogers MJ (2010) Activation of gammadelta T cells by bisphosphonates. Adv Exp Med Biol 658:11-20
85. Terpos E, Dimopoulos MA (2005) Myeloma bone disease: pathophysiology and management. Ann Oncol 16:1223-1231
86. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593-602
87. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384-392
88. Terpos E, Viniou N, de la Fuente J, Meletis J, Voskaridou E, Karkantaris C, Vaiopoulos G, Palermos J, Yataganas X, Goldman JM, Rahemtulla A (2003) Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol 70:34-42
89. Devitt B, McLachlan SA (2008) Use of ibandronate in the prevention of skeletal events in metastatic breast cancer. Ther Clin Risk Manag 4:453-458
90. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191-1200
91. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744
92. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21:3150-3157
93. Naoe M, Ogawa Y, Takeshita K, Morita J, Shichijo T, Fuji K, Fukagai T, Iwamoto S, Terao S (2010) Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncol Res 18:493-501
94. Lipton A (2008) Emerging role of bisphosphonates in the clinic - antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34(suppl 1):S25-S30
95. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459-1468
96. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, Turchi F, Piacentini P, Rocci L, Manavalan JS, Tonini G, Poccia F (2009) In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 58:31-38
97. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, Salesi N, Giannarelli D, Alimonti A, Di Cocco B, D'Agosto G, Bordignon V, Trento E, Cognetti F (2005) Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69:35-43
98. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13:4482-4486
99. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100:1167-1178
100. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113:364-371
101. Rack B, Schindlbeck C, Strobl B, Sommer H, Friese K, Janni W (2008) Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study. Dtsch Med Wochenschr 133:285-289
102. Solomayer E, Gebauer G, Hirnle P, Janni W, Lück H-J, Becker S, Huober J, Kraemer B, Fehm T (2009) Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients (abstract 2048). Cancer Res 69(suppl):170s-171s
103. Aft R, Naughton M, Ylagen L, Watson M, Chavez-MacGregor M, Trinkaus K, Zhai J, Weilbaecher K (2008) Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer (abstract 1021). Presented at the 44th annual meeting of the American society of clinical oncology, 30 May to 3 June 2008, Chicago, IL, USA
104. Lin AY, Park JW, Scott J, Melisko M, Goga A, Moasser MM, Moore DH, Rugo HS (2008) Zoledronic acid as adjuvant therapy for women with early-stage breast cancer and disseminated tumor cells in bone marrow (abstract 559). In: Presented at the 44th annual meeting of the American society of clinical oncology, 30 May to 3 June 2008, Chicago, IL, USA
105. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691
106. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102:1099-1105
107. Coleman R, Bundred N, De Boer R, Llombarto A, Campbell I, Neven P, Barrios C, Dias R, Miller J, Brufsky A (2009) Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, E-ZO-FAST (abstract 4082). Cancer Res 69(suppl):733s
108. Brufsky A, Graydon Harker W, Beck JT, Carroll R, Jin L, Warsi G, Argonza-Aviles E, Ericson S, Perez EA (2009) The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up (abstract 4083). In: Presented at the 32nd annual San Antonio breast cancer symposium, 9 to 13 Dec 2009, San Antonio, TX, USA
109. Costa L, Cook R, Body J-J, Brown J, Terpos E, Saad F, Lipton A, Coleman R (2009) Zoledronic acid treatment delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption (abstract 50) In: Presented at the IX International meeting on cancer induced bone disease, 28-31 Oct 2009, Arlington, VA, USA
110. Body J-J, Cook R, Costa L, Brown J, Terpos E, Saad F, Lipton A, Coleman R (2009) Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features (abstract 71). In: Presented at the IX International Meeting on Cancer Induced Bone Disease, 28-31 October 2009. Arlington, VA, USA
111. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Study Group (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376:1989-1999
112. Zaghloul MS, Boutrus R, El-Hosieny H, A-Kader Y, El-Attar I, Nazmy M (2008) A controlled prospective randomized placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer patients (abstract 5033). J Clin Oncol 26(suppl):257s
113. Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G, Kanakis I, Karamanos NK (2009) The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 125:1705-1709
114. Mystakidou K, Katsouda E, Parpa E, Kelekis A, Galanos A, Vlahos L (2005) Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 22:195-201
115. United States Food and Drug Administration (2009) Background document for meeting of Advisory Committee for Reproductive Health Drugs (13 August). Available from: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/ UCM176605.pdf (Accessed 21 April 2010)
116. Anastasilakis AD, Toulis KA, Polyzos SA, Terpos E (2009) RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opin Investig Drugs 18:1085-1102
117. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765
118. Stopeck A, Body JJ, Fujiwara Y, Lipton A, Steger GG, Viniegra M, Fan M, Braun A, Dansey R, Jun S (2009) Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study (abstract 2LBA). Eur J Cancer Suppl 7:2
119. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Rader M, Shore N, Tadros S, Wang H, Jiang Q, Dansey R, Goessl C (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with castration-resistant prostate cancer (abstract LBA4507). In: Presented at the 46th annual meeting of the American society of clinical oncology, 4-8 June 2010. Chicago, IL, USA
120. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S (2010) Denosumab in patients with giant-cell tumour of bone: an openlabel, phase 2 study. Lancet Oncol 11:275-280
121. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:103-107
122. Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, Terpos E (2009) Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 41:721-729
123. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875-4882
124. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745-755
125. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R (2009) Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 182:509-515; discussion follows
126. Xgeva (denosumab) injection [prescribing information]. Amgen, Thousand Oaks, CA, USA, 2010